Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.

被引：2

作者：

Liu, M. C. ^{[1
]}

Dixon, J. M. ^{[1
]}

Xuan, J. J. ^{[1
]}

Riggins, R. B. ^{[1
]}

Chen, L. ^{[1
]}

Wang, C. ^{[1
]}

Cho, Y. ^{[1
]}

Zhu, Y. ^{[1
]}

Jin, L. ^{[1
]}

Zwart, A. ^{[1
]}

Wang, M. ^{[1
]}

Klimach, U. M. ^{[1
]}

Wang, Y. J. ^{[1
]}

Renshaw, L. ^{[1
]}

Larionov, A. ^{[1
]}

Miller, W. R. ^{[1
]}

Clarke, R. ^{[1
]}

机构：

[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/0008-5472.SABCS11-S1-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

S1-8

引用

页数：1

共 50 条

[41] ERBB2 status and benefit from adjuvant tamoxifen in ERα-positive postmenopausal breast carcinoma
Bièche, I
Onody, P
Lerebours, F
Tozlu, S
Hacene, K
Andrieu, C
Vidaud, M
Tubiana-Hulin, M
Spyratos, F
Lidereau, R
CANCER LETTERS, 2001, 174 (02) : 173 - 178
[42] Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer
Diaz-Gavela, Ana A.
del Cerro, E.
Sanchez-Garcia, S.
Andreu-Vazquez, C.
Thuissard-Vasallo, I. J.
Sanz-Rosa, D.
Pena-Huertas, M.
Ruiz-Morales, C.
Guerrero-Gomez, L. L.
Duque-Santana, V.
Hernandez-Cortes, G.
Gonzalez-Cortijo, L.
Counago, F.
RADIATION ONCOLOGY, 2025, 20 (01)
[43] 10 year event-free survival (EFS) in postmenopausal women with early stage breast cancer during the second five years after adjuvant tamoxifen.
Kennecke, H
Speers, C
Chia, S
Norris, B
Gelmon, K
Bryce, C
Barnett, J
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S57 - S58
[44] Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
Mishra, Ameet K.
Abrahamsson, Annelie
Dabrosin, Charlotta
ONCOTARGET, 2016, 7 (35) : 56876 - 56888
[45] Aromatase inhibitors in the adjuvant treatment of early breast cancer - Is there still a place for tamoxifen?
Bergerat, Jean-Pierre
PRESSE MEDICALE, 2007, 36 (02): : 333 - 340
[46] Aromatase inhibitors declared superior to tamoxifen in the adjuvant treatment of early breast cancer
不详
ONCOLOGY-NEW YORK, 2006, 20 (09): : 1104 - 1105
[47] ADJUVANT TAMOXIFEN IN EARLY BREAST-CANCER - OCCURRENCE OF NEW PRIMARY CANCERS
FORNANDER, T
CEDERMARK, B
MATTSSON, A
SKOOG, L
THEVE, T
ASKERGREN, J
RUTQVIST, LE
GLAS, U
SILFVERSWARD, C
SOMELL, A
WILKING, N
HJALMAR, ML
LANCET, 1989, 1 (8630): : 117 - 120
[48] CARCINOGENIC EFFECTS OF ADJUVANT TAMOXIFEN TREATMENT AND RADIOTHERAPY FOR EARLY BREAST-CANCER
ANDERSSON, M
STORM, HH
MOURIDSEN, HT
ACTA ONCOLOGICA, 1992, 31 (02) : 259 - 263
[49] CONTROLLED TRIAL OF TAMOXIFEN AS ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST-CANCER
BAUM, M
LANCET, 1983, 1 (8319): : 257 - 261
[50] CONTROLLED TRIAL OF ADJUVANT TAMOXIFEN (NOLVADEX) IN THE MANAGEMENT OF EARLY BREAST-CANCER
WILSON, AJ
ANTICANCER RESEARCH, 1986, 6 (03) : 398 - 398

← 1 2 3 4 5 →